In the past, we collected information about emotions and the brain from a variety of clinical and experimental sources, including animals, healthy human beings, and those who had suffered epilepsy, stroke, or other brain injury. In the last decades of the 20th century, the research domains have been expanded by imaging technologies that permit superior and safe investigation of the living brain. This is a major improvement over deducing the regulation of emotional life from accidents or surgical interventions. Imaging technologies make it possible to produce an accurate anatomical picture of a living brain and to document the activity of specific regions. Crucial to the assembly of these new technologies has been sophisticated use of computers and quantitative techniques needed to analyze the deluge of novel information. Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are powerful tools for evaluating changes in blood flow and also for measuring the activity of various receptors. Dr Kennedy and colleagues have written a cogent review of the information that has in recent years quickly accumulated about PET imaging and abnormal moods, depression in particular. The authors' objective was to review the literature on functional PET imaging of mood disorders. The review examines the findings on unipolar and bipolar mood disorders and depressions secondary to neurological disorders and reports observations from cognitive and emotional activation paradigms, as well as psychopharmacological challenge studies. The authors carefully report individual findings, the consensus in the literature about location, and the contradictions about the direction and details of the alterations.
Although relatively new, the imaging approach has already been rewarding. Depressed states in several groups of neurological patients have been consistently found to be associated with regional reductions in brain activity, particularly in orbitofrontal and inferior prefrontal regions. Different PET methods have isolated abnormalities in primary depression in the prefrontal, cingulate, and amygdala regions, which agrees with past correlates of moods.
The authors point out, however, that beyond this consensus, the PET findings diverge widely, particularly as to the direction of the changes. Both hypo-and hypermetabolism have been found by different investigators, particularly in the limbic regions, and differences between depressed and manic patients have varied. The review of activation and treatment studies also reveals contradictory results, with both increases and decreases in posttreatment cerebral activity. The review thus shows not only how valuable this direction of research has proved but also how much additional work needs to be done.
Overall, brain imaging emerges from these studies as a sophisticated technique for dealing with a complex task. And it is not difficult to see why the task is so enigmatic: each human brain may differ slightly in anatomical details. There are many new methodological challenges, which include using correctly the complex mathematical approaches needed to analyze data, selecting the relevant brain centres, and precisely defining their limits. These days there certainly are many practical challenges, as well. The equipment is frightfully expensive, and financing the imaging studies is a major challenge by itself.
Faced with a body of very contradictory data about the direction of the observed changes of brain activity and about the involvement of brain regions other than the 3 major areas already mentioned, one can either give up and wait for more data or attempt to interpret what is available. The authors of our first In Review paper certainly do not give up, offering their overall interpretation that a prefrontal dysfunction and its withdrawal of modulatory activities through frontolimbicparalimbic connections over the subcortical limbic regions may be one of the functional explanations for cognitive, endocrine and, most importantly, mood disturbances in depressive disorders.
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Hypofrontality is indeed the leading finding of a majority of the studies reviewed. Science is not about democracy, however, but about who is right. The history of psychiatric research would hint that a fair portion of findings gathered at this early stage may be artifacts-part of the natural methodological development and varied patient selection-and that we are only gradually learning how to correct and interpret the data.
Concluding that hypofrontality is the major finding of the imaging literature on mood disorders thus far could be disconcerting for another reason. Hypofrontality has now been reported as the major imaging finding in several disorders, particularly in schizophrenia (2) . If most psychiatric disorders showed hypofrontality and low serotonergic function, as it now seems from many research reports, then these sophisticated and expensive investigations would be of little clinical relevance. Dr Kennedy and colleagues forecast that future studies are likely to concentrate on mapping differences in serotonergic system between the depressed and healthy populations, as well as on competition challenges between 5-hydroxytryptamine agonists and antagonists. Thus the clinically most important information generated by PET imaging may be still ahead of us.
Drs Kiran Rabheru and Emmanuel Persad (3) review another major issue in mood disorders, this time along therapeutic lines. The authors review the historical background of prophylactic electroshock, which was introduced in the 1940s and has been the subject of a resurgence of interest in the past decade. This interest seems to be driven by the treatment needs of those severely affectively ill who respond poorly to medication or do not tolerate it. Through continuation-maintenance electroconvulsive therapy (ECT), these patients are provided with an important and often life-saving treatment option. The approach, as the authors point out, may for some patients actually be a safer and more desirable option than long-term pharmacotherapy, and its cost-effectiveness also appears to be very favourable.
The literature strongly suggests that patients with highly recurrent, refractory mood disorders who have responded to an index course of ECT are very suitable candidates for long-term ECT. In patients with a family history of mood disorder, an ECT-induced switch to hypomania/mania remains a significant risk. Particularly informative is the authors' overview of the writings about the value of maintenance ECT beyond affective disorders, in Parkinson's disease, reversible dementia, schizophrenia, and obsessivecompulsive disorder.
Drs Persad and Rabheru gathered an amazing collection of useful but often little-known information about long-term efficacy of ECT. The whole body of data may also be useful to those who wish to ponder the lingering mystery of ECT's mechanism of action.
From this review, it is obvious that continuation-maintenance ECT is a vital tool in the psychiatrist's repertoire. It represents an effective intervention, particularly for those who are otherwise stabilization-resistant. While quantitative data from controlled studies are not plentiful, maintenance ECT appears to be the most effective stabilizing treatment for recurrent primary affective disorders. Geoghegan and Stevenson (4) , in their pioneering 1949 paper, published raw data on recurrence. Using a mirror-image method, anyone can calculate the efficacy the method had in their hands. The results certainly have an edge over any other published data on maintenance treatment in affective disorders, including lithium.
In addition to the extraordinary efficacy of this treatment, there is also a historical reason why Canadians should be aware of it. Although it was first used by Moore, its use spread worldwide only after the Canadian report of Geoghegan and Stevenson in The American Journal of Psychiatry. I had the good fortune to meet Dr Geoghegan in 1969, shortly before his retirement. Based on his own experience, he predicted the difficulty clinicians would face in ensuring that patients adhere to maintenance ECT for longer periods.
This has certainly been my experience, so I was surprised that Drs Rabheru and Persad mention good acceptance of long-term ECT by patients. This is the only point, however, with which I can quarrel in this outstanding review paper, and the authors' experience is probably much greater than mine with geriatric patients, whose adherence to the treatment appears to be better. Finally, the authors also provide an excellent and detailed practical guide for prescribing ECT in prophylactic indications.
It is unfortunate that the use of electroshock, both for acute and prophylactic purposes, became a psychopolitical football and that in recent years the choice of this treatment has often been influenced by much more than clinical considerations. Rabheru and Persad's review paper shows very convincingly how much can be gained by keeping maintenance ECT in our therapeutic repertoire and how much more we could still learn from this long-established technique if we could approach it simply on its clinical and scientific merit.
